Cargando…
JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression
Oncogenic K‐RAS has been difficult to target and currently there is no K‐RAS‐based targeted therapy available for patients suffering from K‐RAS‐driven lung adenocarcinoma (AC). Alternatively, targeting K‐RAS‐downstream effectors, K‐RAS‐cooperating signaling pathways or cancer hallmarks, such as tumo...
Autores principales: | Mohrherr, Julian, Haber, Marcel, Breitenecker, Kristina, Aigner, Petra, Moritsch, Stefan, Voronin, Viktor, Eferl, Robert, Moriggl, Richard, Stoiber, Dagmar, Győrffy, Balázs, Brcic, Luka, László, Viktória, Döme, Balázs, Moldvay, Judit, Dezső, Katalin, Bilban, Martin, Popper, Helmut, Moll, Herwig P., Casanova, Emilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856680/ https://www.ncbi.nlm.nih.gov/pubmed/31407334 http://dx.doi.org/10.1002/ijc.32624 |
Ejemplares similares
-
AKT3 drives adenoid cystic carcinoma development in salivary glands
por: Zboray, Katalin, et al.
Publicado: (2017) -
A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions
por: Moll, Herwig P., et al.
Publicado: (2019) -
Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis
por: Grabner, Beatrice, et al.
Publicado: (2015) -
STAT3: Versatile Functions in Non-Small Cell Lung Cancer
por: Mohrherr, Julian, et al.
Publicado: (2020) -
From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
por: Lohinai, Zoltan, et al.
Publicado: (2016)